PharmaSGP Holding Future Growth

Future criteria checks 3/6

PharmaSGP Holding is forecast to grow earnings and revenue by 8.8% and 6.8% per annum respectively. EPS is expected to grow by 8.4% per annum. Return on equity is forecast to be 36.8% in 3 years.

Key information

8.8%

Earnings growth rate

8.4%

EPS growth rate

Pharmaceuticals earnings growth	20.7%
Revenue growth rate	6.8%
Future return on equity	36.8%
Analyst coverage	Low
Last updated	03 May 2024

Recent future growth updates

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

May 06

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Mar 02

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Dec 02

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

Feb 16

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

Jan 26

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Dec 04

Earnings and Revenue Growth Forecasts

XTRA:PSG - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	125	22	N/A	32	2
12/31/2025	116	19	27	30	2
12/31/2024	109	18	26	27	1
12/31/2023	101	16	26	27	N/A
9/30/2023	98	15	25	26	N/A
6/30/2023	94	14	22	23	N/A
3/31/2023	89	13	28	28	N/A
12/31/2022	86	12	24	25	N/A
9/30/2022	83	11	34	35	N/A
6/30/2022	81	11	-64	19	N/A
3/31/2022	74	11	-71	12	N/A
12/31/2021	65	11	-71	12	N/A
9/30/2021	61	8	-89	-6	N/A
6/30/2021	56	8	8	8	N/A
3/31/2021	59	9	12	13	N/A
12/31/2020	63	11	15	15	N/A
9/30/2020	65	16	18	19	N/A
6/30/2020	65	17	17	18	N/A
3/31/2020	64	17	20	20	N/A
12/31/2019	63	17	17	18	N/A
12/31/2018	61	15	8	8	N/A
12/31/2017	53	12	14	14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PSG's forecast earnings growth (8.8% per year) is above the savings rate (0.7%).

Earnings vs Market: PSG's earnings (8.8% per year) are forecast to grow slower than the German market (17% per year).

High Growth Earnings: PSG's earnings are forecast to grow, but not significantly.

Revenue vs Market: PSG's revenue (6.8% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: PSG's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PSG's Return on Equity is forecast to be high in 3 years time (36.8%)

PharmaSGP Holding Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

Consensus EPS estimates increase by 11%

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Recent updates

Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Consensus EPS estimates increase by 10%

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Consensus EPS estimates increase by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

PharmaSGP Holding SE Just Beat Revenue Estimates By 25%

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

Investor sentiment improved over the past week

Consensus forecasts updated

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

Analysts lower EPS estimates to €0.95

One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential

New 90-day low: €19.76

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Market pulls back on stock over the past week

Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?

Analysts lower EPS estimates to €1.13

New 90-day low: €27.00

New 90-day low: €28.75

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies